Advancing Brain Disorder Treatments with Ultrasound Technology
NaviFUS Corp. is leading a transformative approach in the treatment of brain disorders through its innovative ultrasound-based solutions. With its roots in Taiwan’s advanced chip technology, NaviFUS has managed to integrate cutting-edge ICT capabilities into high-end medical devices. This unique combination not only elevates the signal processing quality but also enables NaviFUS to assert itself as a forerunner in focused ultrasound treatments globally.
Innovative Technology: Changing Lives
Transcranial Focused Ultrasound
The NaviFUS system employs transcranial focused ultrasound technology, coupled with therapeutic guidance tracking, to enhance drug delivery and neuromodulation. This groundbreaking method opens new possibilities for patients grappling with severe conditions like brain cancer and drug-resistant epilepsy.
Industry Support and Collaborative Effort
Partnerships Driving Progress
With robust backing from prestigious venture capitalists, including prominent figures like Andy T.C. Chiu of Top Taiwan Venture Capital, Stan Shih of Acer, and Max Wu from the Spring Foundation of NCTU, NaviFUS is well-positioned for success. The company’s collaboration with notable organizations such as YoungTek Electronics Corp. and Genovate Biotechnology Co., Ltd., as well as the Focused Ultrasound Foundation led by Dr. Neal Kassell, further accelerates the development and implementation of their innovative technologies.
Clinical Achievements: Pioneering Trials
Promising Results in Recent Trials
NaviFUS has recently completed a successful Phase II trial using Avastin for treating recurrent glioblastoma (rGBM). The results demonstrated a remarkable 66.7% progression-free survival rate at six months, surpassing the historical average of 42.6%. Additionally, the median progression-free survival achieved by the NaviFUS system was recorded at 8.9 months, notably exceeding the previous standard of 4.2 months.
Furthermore, preliminary studies in drug-resistant epilepsy indicate that the NaviFUS system significantly decreases both seizure frequency and duration, making considerable strides towards effective treatment options for patients who have not responded to conventional medication. Currently, Phase II trials are underway in Taiwan, with pilot studies expanding to new territories such as Australia and the United States.
Expanding Global Presence through Collaboration
Partnership with Brainlab
NaviFUS is enhancing its global presence through strategic partnerships, notably with Brainlab, a titan in surgical navigation. This collaboration facilitates enhanced precision in treatment procedures, leveraging Brainlab's extensive network of around 6,300 hospitals in 120 countries, allowing NaviFUS to reach patients worldwide.
Highlighting Taiwan's Commitment to Healthcare Innovation
Chairman Jen Chen has articulated Taiwan's promise towards advancing biomedical technology, a message reiterated by Acer founder Stan Shih during presentations leading up to NaviFUS’s listing. As the only high-end medical device enterprise in Taiwan combining superior chip technology with focused ultrasound methods, NaviFUS stands at the forefront of a new era in non-invasive brain treatment solutions.
About NaviFUS Corp.
NaviFUS Corp. is pioneering focused ultrasound (FUS) technology that promotes blood-brain barrier opening, enhancing drug delivery systems and neuromodulation. This advancement aims to significantly improve treatment outcomes for brain diseases such as glioblastoma and epilepsy.
Frequently Asked Questions
What is NaviFUS Corp. focused on?
NaviFUS Corp. focuses on developing ultrasound-based solutions for treating brain disorders, specifically targeting conditions like glioblastoma and epilepsy.
How does the NaviFUS technology work?
The technology employs transcranial focused ultrasound to deliver therapeutic guidance, enhancing drug delivery and neuromodulation for patients suffering from severe brain conditions.
What partnerships support NaviFUS?
NaviFUS collaborates with several prominent organizations, including YoungTek Electronics Corp., Genovate Biotechnology Co., Ltd., and the Focused Ultrasound Foundation.
What are the clinical outcomes of NaviFUS trials?
Recent trials have shown a 66.7% progression-free survival in treating recurrent glioblastoma, exceeding previous benchmarks and demonstrating the technology's effectiveness.
Is NaviFUS expanding internationally?
Yes, NaviFUS is strategically expanding its reach globally through partnerships, notably with Brainlab, to improve treatment precision in hospitals around the world.
